FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Apr. 1, 2015--
MEDNAX, Inc. (NYSE: MD), today announced the acquisition of Texas Ear,
Nose & Throat Consultants, PLLC, locally-known as Children’s ENT of
Houston, located in Houston, Texas.
Children’s ENT of Houston is a private physician group practice with
three office-based locations that employ three ENT specialists, two
audiologists, two nurse practitioners and 15 other clinical and
administrative staff. The practice, through a related entity included in
the transaction, performs more than 15,000 newborn hearing screens
annually at The Woman’s Hospital of Texas, Children's Memorial Hermann
Hospital and Conroe Regional Medical Center. The practice has been
providing hearing screen services at Woman's Hospital since 2005.
“We are excited about this partnership because our patients will
ultimately benefit from the infrastructure and support that MEDNAX
provides to address the challenges of an increasingly complex healthcare
industry. This will allow our team of healthcare professionals to
concentrate wholly on what is best for our patients,” said Joseph
Edmonds, M.D., who will serve as medical director for the practice. “In
addition, being part of a physician-led, national medical group that is
committed to research, education and quality, will allow us to
contribute to research that will improve the quality of care for our
patients and our community.”
The acquisition of Children’s ENT expands the continuum of care MEDNAX
currently provides at The Woman’s Hospital of Texas, which includes
perinatal services, neonatal services at the hospital's Level II and
Level III neonatal intensive care units, pediatric cardiology and
anesthesia. It also enhances the services MEDNAX provides throughout the
greater-Houston market.
This was a cash transaction, and it is expected to be immediately
accretive to earnings. No additional terms of the transaction were
disclosed.
ABOUT MEDNAX
MEDNAX, Inc. is a national medical group comprised of the nation's
leading providers of neonatal, anesthesia, maternal-fetal and pediatric
physician subspecialty services. Physicians and advanced practitioners
practicing as part of MEDNAX are reshaping the delivery of care within
their specialties and subspecialties, using evidence-based tools,
continuous quality initiatives and clinical research to enhance patient
outcomes and provide high-quality, cost-effective care. Pediatrix
Medical Group, a division of MEDNAX, was founded in 1979 and includes
neonatal physicians who provide services at more than 370 neonatal
intensive care units, and collaborate with affiliated maternal-fetal
medicine, pediatric cardiology, pediatric critical care and other
physician subspecialists to provide a clinical care continuum. Pediatrix
is also the nation's largest provider of newborn hearing screens.
American Anesthesiology, a division of MEDNAX, was established in 2007
and includes more than 2,400 anesthesiologists and advanced
practitioners who provide anesthesia care to patients in connection with
surgical and other procedures as well as pain management. MEDNAX,
through its affiliated professional corporations, employs more than
2,650 physicians in 34 states and Puerto Rico. In addition to its
national physician network, MEDNAX provides services to medical
providers in over 40 states through two complementary businesses,
consisting of a revenue cycle management company and a consulting
services company. Additional information is available at www.mednax.com.
Certain statements and information in this press release may be
deemed to contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking statements may
include, but are not limited to, statements relating to our objectives,
plans and strategies, and all statements, other than statements of
historical facts, that address activities, events or developments that
we intend, expect, project, believe or anticipate will or may occur in
the future. These statements are often characterized by terminology such
as “believe”, “hope”, “may”, “anticipate”, “should”, “intend”, “plan”,
“will”, “expect”, “estimate”, “project”, “positioned”, “strategy” and
similar expressions, and are based on assumptions and assessments made
by MEDNAX’s management in light of their experience and their perception
of historical trends, current conditions, expected future developments
and other factors they believe to be appropriate. Any forward-looking
statements in this press release are made as of the date hereof, and
MEDNAX undertakes no duty to update or revise any such statements,
whether as a result of new information, future events or otherwise.
Forward-looking statements are not guarantees of future performance and
are subject to risks and uncertainties. Important factors that could cause
actual results, developments, and business decisions to differ
materially from forward-looking statements are described in MEDNAX’s
most recent Annual Report on Form 10-K and its Quarterly Reports on Form
10-Q, including the sections entitled “Risk Factors”, as well MEDNAX’s
current reports on Form 8-K, filed with the Securities and
Exchange Commission.
Source: MEDNAX, Inc.
MEDNAX, Inc.
Charles Lynch, 954-384-0175, x 5692
Vice
President, Strategy and Investor Relations
charles_lynch@mednax.com